FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156871508> ?p ?o ?g. }

• W2156871508 endingPage "4300" @default.
• W2156871508 startingPage "4293" @default.
• W2156871508 abstract "This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients.Patients with inoperable HCC, no prior systemic treatment, and Child-Pugh (CP) A or B, received continuous, oral sorafenib 400 mg bid in 4-week cycles. Tumor response was assessed every two cycles using modified WHO criteria. Sorafenib pharmacokinetics were measured in plasma samples. Biomarker analysis included phosphorylated extracellular signal regulated kinase (pERK) in pretreatment biopsies (immunohistochemistry) and blood-cell RNA expression patterns in selected patients.Of 137 patients treated (male, 71%; median age, 69 years), 72% had CP A, and 28% had CP B. On the basis of independent assessment, three (2.2%) patients achieved a partial response, eight (5.8%) had a minor response, and 46 (33.6%) had stable disease for at least 16 weeks. Investigator-assessed median time to progression (TTP) was 4.2 months, and median overall survival was 9.2 months. Grade 3/4 drug-related toxicities included fatigue (9.5%), diarrhea (8.0%), and hand-foot skin reaction (5.1%). There were no significant pharmacokinetic differences between CP A and B patients. Pretreatment tumor pERK levels correlated with TTP. A panel of 18 expressed genes was identified that distinguished nonprogressors from progressors with an estimated 100% accuracy.Although single-agent sorafenib has modest efficacy in HCC, the manageable toxicity and mechanisms of action support a role for combination regimens with other anticancer agents." @default.
• W2156871508 created "2016-06-24" @default.
• W2156871508 creator A5004762787 @default.
• W2156871508 creator A5011642439 @default.
• W2156871508 creator A5024245359 @default.
• W2156871508 creator A5045588447 @default.
• W2156871508 creator A5056035743 @default.
• W2156871508 creator A5058825770 @default.
• W2156871508 creator A5058908254 @default.
• W2156871508 creator A5066167770 @default.
• W2156871508 creator A5075055655 @default.
• W2156871508 creator A5081273660 @default.
• W2156871508 creator A5081718657 @default.
• W2156871508 creator A5082045927 @default.
• W2156871508 creator A5085712563 @default.
• W2156871508 date "2006-09-10" @default.
• W2156871508 modified "2023-10-14" @default.
• W2156871508 title "Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma" @default.
• W2156871508 cites W1792128361 @default.
• W2156871508 cites W1973514550 @default.
• W2156871508 cites W1976048849 @default.
• W2156871508 cites W1991938154 @default.
• W2156871508 cites W2035635916 @default.
• W2156871508 cites W2038447145 @default.
• W2156871508 cites W2046177464 @default.
• W2156871508 cites W2057492361 @default.
• W2156871508 cites W2059072983 @default.
• W2156871508 cites W2069828593 @default.
• W2156871508 cites W2093083587 @default.
• W2156871508 cites W2094943413 @default.
• W2156871508 cites W2099774889 @default.
• W2156871508 cites W2101031676 @default.
• W2156871508 cites W2109043126 @default.
• W2156871508 cites W2112785482 @default.
• W2156871508 cites W2116177733 @default.
• W2156871508 cites W2133559579 @default.
• W2156871508 cites W2140765540 @default.
• W2156871508 cites W2187668060 @default.
• W2156871508 cites W2321119966 @default.
• W2156871508 doi "https://doi.org/10.1200/jco.2005.01.3441" @default.
• W2156871508 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16908937" @default.
• W2156871508 hasPublicationYear "2006" @default.
• W2156871508 type Work @default.
• W2156871508 sameAs 2156871508 @default.
• W2156871508 citedByCount "1096" @default.
• W2156871508 countsByYear W21568715082012 @default.
• W2156871508 countsByYear W21568715082013 @default.
• W2156871508 countsByYear W21568715082014 @default.
• W2156871508 countsByYear W21568715082015 @default.
• W2156871508 countsByYear W21568715082016 @default.
• W2156871508 countsByYear W21568715082017 @default.
• W2156871508 countsByYear W21568715082018 @default.
• W2156871508 countsByYear W21568715082019 @default.
• W2156871508 countsByYear W21568715082020 @default.
• W2156871508 countsByYear W21568715082021 @default.
• W2156871508 countsByYear W21568715082022 @default.
• W2156871508 countsByYear W21568715082023 @default.
• W2156871508 crossrefType "journal-article" @default.
• W2156871508 hasAuthorship W2156871508A5004762787 @default.
• W2156871508 hasAuthorship W2156871508A5011642439 @default.
• W2156871508 hasAuthorship W2156871508A5024245359 @default.
• W2156871508 hasAuthorship W2156871508A5045588447 @default.
• W2156871508 hasAuthorship W2156871508A5056035743 @default.
• W2156871508 hasAuthorship W2156871508A5058825770 @default.
• W2156871508 hasAuthorship W2156871508A5058908254 @default.
• W2156871508 hasAuthorship W2156871508A5066167770 @default.
• W2156871508 hasAuthorship W2156871508A5075055655 @default.
• W2156871508 hasAuthorship W2156871508A5081273660 @default.
• W2156871508 hasAuthorship W2156871508A5081718657 @default.
• W2156871508 hasAuthorship W2156871508A5082045927 @default.
• W2156871508 hasAuthorship W2156871508A5085712563 @default.
• W2156871508 hasBestOaLocation W21568715081 @default.
• W2156871508 hasConcept C112705442 @default.
• W2156871508 hasConcept C121608353 @default.
• W2156871508 hasConcept C126322002 @default.
• W2156871508 hasConcept C143998085 @default.
• W2156871508 hasConcept C185592680 @default.
• W2156871508 hasConcept C2778019345 @default.
• W2156871508 hasConcept C2778695046 @default.
• W2156871508 hasConcept C2778820342 @default.
• W2156871508 hasConcept C2779984678 @default.
• W2156871508 hasConcept C2781197716 @default.
• W2156871508 hasConcept C29730261 @default.
• W2156871508 hasConcept C31760486 @default.
• W2156871508 hasConcept C55493867 @default.
• W2156871508 hasConcept C71924100 @default.
• W2156871508 hasConcept C90924648 @default.
• W2156871508 hasConcept C98274493 @default.
• W2156871508 hasConceptScore W2156871508C112705442 @default.
• W2156871508 hasConceptScore W2156871508C121608353 @default.
• W2156871508 hasConceptScore W2156871508C126322002 @default.
• W2156871508 hasConceptScore W2156871508C143998085 @default.
• W2156871508 hasConceptScore W2156871508C185592680 @default.
• W2156871508 hasConceptScore W2156871508C2778019345 @default.
• W2156871508 hasConceptScore W2156871508C2778695046 @default.
• W2156871508 hasConceptScore W2156871508C2778820342 @default.
• W2156871508 hasConceptScore W2156871508C2779984678 @default.
• W2156871508 hasConceptScore W2156871508C2781197716 @default.

• next